Photocure ASA : Third Quarter 2011 results
Photocure ASA - Third quarter 2011 results
Oslo, Norway, 26 October 2011.
The main highlight in the third quarter was the creation of a new commercial strategy for Hexvix®, Photocure's flagship product to aid in diagnosing bladder cancer. Photocure has entered into a strategic collaboration with Ipsen, a global specialty-driven biopharmaceutical company to commercialise Hexvix worldwide, excluding USA and Nordic region. Additionally, to capitalise on the untapped market opportunity in USA, Photocure plans to launch the product, approved as Cysview(TM) in USA, through its own commercial operations. The new strategy will maximise the potential of Hexvix on a global basis.
Additional highlights include:
- Continued launch of Allumera® on the US market by Photocure's dedicated commercial organization
- Started recruitment in phase IIb study for Visonac®, creating the platform for phase III
- Sales revenues growing 41% to NOK 20.6 million (NOK 14.6 million) in Q3 2011
- Net loss NOK 6.8 million (NOK 11.6 million) in Q3 2011
- Cash holding of NOK 336.1 million per 30 September 2011
|Figures in NOK millions||Q3 2011||Q3 2010||YTD2011||YTD2010||Full year 2010|
|Signing fee & milestone revenues||11.7||0||11.7||83 .4||106.8|
|Research and development expenses||13.8||13.0||45.0||52.3||90.2|
|Sales and marketing expenses||12.1||9.4||33.7||24.9||35.4|
|Operating result (EBIT)||-10.6||-15.9||-48.9||27.2||7.5|
|Earnings per share, diluted (NOK)||-0.31||-0.52||-1.91||1.57||0.83|
Please find the full report enclosed.
Photocure ASA will present its third quarter 2011 report on Wednesday 26th of October 2011 at Shippingklubben, Haakon VIIs gate 1 (top floor), Oslo, Norway. The presentation will begin at 11.30 (CET) and representatives from the company will be Kjetil Hestdal, President & CEO and Christian Fekete, CFO.
For more information, please contact:
Kjetil Hestdal, President and CEO
Mobile: +47 913 19535
Christian Fekete, CFO
Mobile: +47 916 42 938